This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Mar 2011

Repligen Bipolar Depression Drug Fails Phase IIb Study

The company plans to conduct further evaluation of the data to determine if there is a path forward with RG2417.

Repligen Corporation has reported results from a Phase IIb clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.


The double-blind, placebo-controlled trial enrolled 175 patients at 12 academic and 17 commercial study sites. The patients were randomised in a 1:1 ratio to receive either RG2417 or a placebo twice a day for eight weeks.


The study did not show a statistically significant improvement in the symptoms of depression in patients treated with RG2417 when compared to placebo over the eight-week treatment period.


Related News